1. Pink Sheet
  2. >>Geography

EU Approval Nod Possible For Novartis, Gilead/Galapagos, and Janssen

CHMP Marketing Opinions Are Due On Alpelisib, Filgotinib, Ebola Vaccines

 
• By Maureen Kenny

The May meeting of the European Medicines Agency’s drug evaluation committee, the CHMP, is under way. Decisions are due on whether eight marketing approval applications should be approved for marketing in the EU.

White_Pills_Blue_Gloves
Some new drugs will edge closer to EU approval this week • Source: Shutterstock

Piqray (alpelisib), Novartis’s first-in-class PI3K inhibitor for treating a specific sub-type of advanced breast cancer, could be approved in the EU in a matter of months.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography